



## ASX Announcement

13 November 2023

*Not for release to US wire services or distribution in the United States*

### Entitlement offer opens and dispatch of Offer Booklet to Eligible Shareholders

On Friday, 3 November 2023, Anatara Lifesciences Limited (ASX: ANR) ("**Anatara**" or the "**Company**") announced the launch of a A\$1.055 million entitlement offer of new fully paid ordinary shares (**New Shares**) at an offer price of A\$0.022 per New Share (**Offer Price**) (**Entitlement Offer**).

The Entitlement Offer is comprised of a partially underwritten<sup>1</sup> 2 - for- 5 pro rata non-renounceable entitlement offer of New Shares to raise gross proceeds of approximately A\$1.055 million.

It is expected that approximately 47,969,594 New Shares will be issued under the Entitlement Offer (equating to approximately 28.5% of all the issued shares in the Company following completion of the Entitlement Offer).

The Entitlement Offer is partially underwritten by Taylor Collison Limited (**Underwriter**) up to approximately A\$360,000 (**Underwritten Amount**).

Directors, David Brookes and John Michailidis have committed to take up their full Entitlement and sub-underwrite the Entitlement Offer to an additional A\$33,000 and A\$5,500 respectively.

The Entitlement Offer is being made without a prospectus or disclosure document in accordance with section 708AA of the Corporations Act 2001 (Cth).

The New Shares will rank equally in all respects with Anatara's existing shares. If an eligible shareholder's entitlement results in a fraction of a New Share, the shareholder's entitlement will be rounded up to the nearest whole number.

Attached is a copy of the offer booklet for the Entitlement Offer (**Offer Booklet**) which will be made available to Eligible Shareholders either by email (if they have elected to receive electronic communications only), online or by post together with a personalised Entitlement and Acceptance Form. A copy of the Offer Booklet is also accessible at <https://www2.asx.com.au>.

Also attached is a sample of a letter that will be made available to SenSen shareholders who are eligible to participate, notifying them of the Entitlement Offer.

The Entitlement Offer is now open and closes at 5.00pm (Melbourne time) on **Friday, 1 December 2023** (unless extended).

---

<sup>1</sup> Refer to the Offer Booklet for a description of the terms and conditions of the underwriting arrangement.

The Offer Booklet and the Entitlement and Acceptance Form contain important information about the Entitlement Offer, including how eligible shareholders can apply to participate in the Entitlement Offer.

### Key Dates

Item	Date
ASX announcement of Entitlement Offer	Friday, 3 November 2023
Ex date	Tuesday, 7 November 2023
Record date for Entitlement Offer	7pm (Melbourne time) Wednesday, 8 November 2023
Despatch date Entitlement Offer opens	Monday, 13 November 2023
Last date to extend Entitlement Offer closing date	Tuesday, 28 November 2023
Entitlement Offer close	5pm (Melbourne time) Friday, 1 December 2023
Announcement of Entitlement Offer results	Thursday, 7 December 2023
Entitlement Offer – Settlement Date	Thursday, 7 December 2023
Issue Date	Before 12.00pm (Melbourne time) Friday, 8 December 2023
Despatch Date Trading in Entitlement Offer Shares	Monday, 11 December 2023

This timetable is indicative only and may be subject to change without notice to, or consultation with, you. Anantara reserves the right to amend any or all of these dates and times subject to the *Corporations Act 2001* (Cth), the ASX Listing Rules and other applicable laws. In particular, Anantara reserves the right to extend the closing date for the Entitlement Offer, to accept late applications under the Entitlement Offer (either generally or in particular cases) and to withdraw the Entitlement Offer without prior notice. Any extension of the closing date for the Entitlement Offer will have a consequential effect on the allotment date of Shares. Anantara also reserves the right not to proceed with the Entitlement Offer in whole or in part at any time prior to allotment and issue of the relevant Shares. In that event, the relevant application monies (without interest) must be returned in full to applicants.

We look forward to keeping the market updated with further material progress.

This announcement has been approved by the Board of Anantara Lifesciences Limited.

—ENDS—

### For more information please contact:

#### General inquiries

David Brookes  
Chair, Anantara Lifesciences Ltd  
+61 (0) 411 712 579  
[dbrookes@anantara.com](mailto:dbrookes@anantara.com)

Dirk van Dissel  
Candour Advisory – Investor Relations  
+61 (0) 408 326 367  
[dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

### About Anantara Lifesciences Ltd

Anantara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anantara is a life sciences company with expertise in developing products for animal and human health. Anantara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

### Disclaimer

### Forward looking statements

This document contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this document are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Anantara, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Anantara's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Anantara, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this document. The forward-looking statements are based on information available to Anantara as at the date of this document. Except as required by law or regulation (including the ASX Listing Rules), none of Anantara, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

### Not an offer in the United States

This document has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any other jurisdiction in which such an offer would be illegal. Any securities described in this document have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "US Securities Act") or the securities laws of any state or jurisdiction of the United States. Accordingly, the securities described in this document may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and applicable securities laws of any state or other jurisdiction of the United States.